

**Overview**

Syneron Medical Ltd. (NASDAQ: ELOS) is the leading global aesthetic device company with a comprehensive product portfolio and a global distribution footprint. The Company's technology enables physicians to provide advanced solutions for a broad range of medical-aesthetic applications including body contouring, hair removal, wrinkle reduction, rejuvenation of the skin's appearance through the treatment of superficial benign vascular and pigmented lesions, and the treatment of acne, leg veins and cellulite. The Company sells its products under two distinct brands, Syneron and Candela. Founded in 2000, the corporate, R&D, and manufacturing headquarters for Syneron Medical Ltd. are located in Israel. Syneron also has R&D and manufacturing operations in the US. The company markets, services and supports its products in 86 countries. It has offices in North America, France, Germany, Italy, Portugal, Spain, UK, Australia, China, Japan, and Hong Kong and distributors worldwide. Additional information can be found at [www.syneron.com](http://www.syneron.com)

**Market Data**

(as of January 5, 2010)

Ticker Symbol(NASDAQ)	<b>ELOS</b>
Recent price	\$10.39
52 week range	\$4.55 - \$12.44
Market Cap	\$286 million

**Financial Highlights**


(\$ in millions except per share data)

<b>Income Statement</b>	<b>3Q09</b>	<b>3Q08</b>
Revenues	14.3	28.5
Net (loss) Income	(5.5)	2.2
eps (fully diluted)	(0.20)	0.08
<b>Balance Sheet</b>	<b>9/30/09</b>	<b>12/31/08</b>
Cash & equivalents	213.3	217.1
Total assets	257.9	281.3
Shareholders' equity	228.1	242.6

**Investment Highlights**

- The leading global aesthetic device company with approx. 30% WW market share
- Most comprehensive product portfolio addressing largest and fastest growing aesthetic device markers
- Proprietary elōs technology provides superior, repeatable results with enhanced safety
- New business models designed to address economic changes and to diversify corporate revenue base
- Balanced mix of physician customers
- Exceptional customer responsiveness with guaranteed depot service
- Largest worldwide sales/distribution and service network
- Attractive financial profile with approx. \$240 million in cash with over \$180 million created from operations and zero debt

**Sales by Geographical Area (Q3 2009)**




## Management

Shimon Eckhouse	Chairman of the Board
Louis Scafuri	CEO
Fabian Tenenbaum	CFO
Karen Sarid	President & GM Syneron Israel
Boris Vaynberg	VP R&D

## Syneron Annual Sales

(U.S. \$ in millions)



## Recent Events

- Jan 2010 Syneron Medical Ltd. successfully completes merger with Candela Corporation - Creates the leader in the aesthetic device industry
- Nov 2009 Syneron debuts elure™ Advanced Dermal Whitening in Asia
- Oct 2009 Syneron Medical Ltd. to Acquire Primaeva Medical, Inc.
- Jun 2009 Syneron launches the Syneron Advantage™ – a new physician partnership program to support customers' financial and business needs in today's economic climate
- Jun 2009 Syneron introduces a new and unique treatment modality called Sublative Rejuvenation™ and releases VelaShape II™, with increased RF energy for quicker non-invasive procedures leading to body contouring

## Product Platform

### eLight



A complete elōs facial solution

### eLaser



Diode laser elōs technology

### eMax



A complete aesthetic elōs workstation

### VelaShape II



A cellulite and body shaping solution

### LipoLite



Laser-assisted lipolysis

### eMatrix



A portable skin resurfacing system